Anebulo Pharmaceuticals, Inc. (OTCMKTS:ANEB – Get Free Report) shares fell 5.5% during mid-day trading on Thursday. The stock traded as low as $0.26 and last traded at $0.26. Approximately 100 shares changed hands during mid-day trading, a decline of 45% from the average daily volume of 183 shares. The stock had previously closed at $0.2750.
Anebulo Pharmaceuticals Stock Performance
The stock has a market capitalization of $10.60 million, a price-to-earnings ratio of -1.37 and a beta of -1.88. The firm’s fifty day simple moving average is $0.31 and its 200 day simple moving average is $0.48.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and related medical emergencies. The company’s work is aimed at addressing the effects of cannabis and synthetic cannabinoids, including situations in which patients require urgent medical care.
Anebulo’s lead investigational product, ANEB-001, is an orally administered antagonist of the cannabinoid type 1 (CB1) receptor. The company is developing ANEB-001 to rapidly reverse the effects of cannabinoid intoxication, with potential applications in emergency and acute-care settings.
Featured Articles
- Five stocks we like better than Anebulo Pharmaceuticals
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
